Kineta Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	1.8yrs
Promedio de permanencia en la Junta Directiva	1.8yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Kineta no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Craig Philips	President & Secretary	1.8yrs	US$993.40k	0.78% $ 65.6k
Keith Baker	Chief Financial Officer	1.8yrs	US$813.69k	0.14% $ 11.6k
Thierry Guillaudeux	Chief Scientific Officer	1.8yrs	sin datos	0.18% $ 14.9k
Gary Gentges	Executive Vice President of Corporate Development	no data	sin datos	sin datos
Pauline Kenny	Advisor	less than a year	US$741.73k	0.15% $ 12.7k

1.8yrs

Permanencia media

56.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de KA no se considera experimentado ( 1.5 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
David Arkowitz	Independent Director	1.8yrs	US$141.55k	0.023% $ 1.9k
Kimberlee Drapkin	Independent Director	1.3yrs	US$69.85k	0% $ 0
Shawn P. Iadonato	Chairman of the Board	1.8yrs	US$1.28m	5.62% $ 473.0k
Raymond Bartoszek	Independent Director	1.8yrs	US$86.37k	14.68% $ 1.2m
Marion Foote	Independent Director	1.8yrs	US$90.12k	1.17% $ 98.4k
Scott Dylla	Independent Director	1.3yrs	US$66.10k	0.033% $ 2.7k
Richard Peters	Lead Independent Director	1.8yrs	US$148.18k	0.73% $ 61.8k
Lisa Coussens	Member of Scientific Advisory Board	4.5yrs	sin datos	sin datos
Patricia LoRusso	Member of Scientific Advisory Board	4.5yrs	sin datos	sin datos
Michael Curran	Member of Scientific Advisory Board	4.5yrs	sin datos	sin datos
Evan Yu	Member of Scientific Advisory Board	1.6yrs	sin datos	sin datos
Myriam Chalabi	Member of Scientific Advisory Board	1.6yrs	sin datos	sin datos

1.8yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de KA no se considera experimentada (1.5 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Kineta Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

High number of new and inexperienced directors

Kineta, Inc., Annual General Meeting, Jun 21, 2024

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Announces Board Appointments

No independent directors

Recent updates

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

Kineta, Inc. Announces the Extension of the TuHura Biosciences Exclusivity and Right of First Offer Agreement for KVA12123

Kineta, Inc.(OTCPK:KANT) dropped from S&P TMI Index

Nasdaq Suspends Trading of Kineta's Common Stock Following Denial of Continued Listing Request, Effective September 19, 2024 and to File Form 25-NSE with the Securities and Exchange Commission

Kineta, Inc.(OTCPK:KANT) dropped from NASDAQ Composite Index

Nasdaq Listing Qualifications Staff Denies Kineta, Inc.'s Request for Continued Listing on the Nasdaq Capital Market

Nasdaq Listing Qualifications Staff Denies Kineta, Inc.'s Request for Continued Listing on the Nasdaq Capital Market

Kineta, Inc. Re Opens Enrollment for the Vista-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

Kineta Receives Written Notice from the Listing Qualifications Department of the Nasdaq Regarding No Longer Complies with the Requirement Under Nasdaq Listing Rule 5550(b)(1)

High number of new and inexperienced directors

Kineta, Inc., Annual General Meeting, Jun 21, 2024

Kineta Receives Written Notice from Nasdaq Regarding Non-Compliance Minimum Closing Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial

Kineta, Inc. Announces an Update on Its Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating Kva12123

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO

Kineta, Inc. Announces Restructuring and Workforce Reduction

Kineta, Inc. Announces Update on Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Tumor Activity

Kineta, Inc. Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s 38th Annual Meeting

Kineta, Inc. Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Advanced Solid Tumors

Kineta, Inc. Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 Vista-101 Clinical Trial

New major risk - Share price stability

Kineta Regains Compliance with Nasdaq Listing Rules

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Kineta, Inc. Announces Board Appointments

Third quarter 2022 earnings released

No independent directors

Kineta, Inc. completed the acquisition of Yumanity Therapeutics, Inc. (NasdaqCM:YMTX) from a group of shareholders in a reverse merger transaction.

CEO

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad